News
ACAD
27.52
-1.11%
-0.31
Weekly Report: what happened at ACAD last week (0907-0911)?
Weekly Report · 1d ago
Acadia Pharmaceuticals Reaches Preliminary Derivative Lawsuit Settlement
TipRanks · 3d ago
Acadia Pharmaceuticals Receives Preliminary Court Approval Of Settlement Of Kanner Et Al. V. Biggar Et Al. Derivative Action
Benzinga · 3d ago
Weekly Report: what happened at ACAD last week (0831-0904)?
Weekly Report · 09/07 09:26
Should EU Approval of First Rett Syndrome Therapy DAYBU Reshape ACADIA Pharmaceuticals’ (ACAD) Investment Narrative?
Simply Wall St · 09/07 05:23
ACADIA Pharmaceuticals (ACAD) Wins EU Approval For DAYBU, Is The 16% Upside Still There?
Simply Wall St · 09/05 22:22
Canaccord Genuity Reaffirms Their Buy Rating on ACADIA Pharmaceuticals (ACAD)
TipRanks · 09/03 10:56
Trump Admin To Target Biotechs With Curbs On Drug Pricing? What Investors Should Know
Seeking Alpha · 08/31 18:57
Weekly Report: what happened at ACAD last week (0824-0828)?
Weekly Report · 08/31 09:29
Did First-in-Class EU Approval for DAYBU Just Shift ACADIA Pharmaceuticals' (ACAD) Investment Narrative?
Simply Wall St · 08/28 17:38
Is ACADIA Pharmaceuticals (ACAD) Still Trading At A Discount As DAYBU Wins EU Approval?
Simply Wall St · 08/26 21:29
ACADIA Pharmaceuticals Is Maintained at Buy by Deutsche Bank
Dow Jones · 08/25 17:16
Deutsche Bank Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $38
Benzinga · 08/25 17:05
ACADIA Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
Dow Jones · 08/25 15:38
ACADIA Pharmaceuticals Is Maintained at Buy by Citigroup
Dow Jones · 08/25 15:37
ACADIA Pharmaceuticals Price Target Raised to $40.00/Share From $39.00 by Citigroup
Dow Jones · 08/25 15:37
Morgan Stanley Maintains Equal-Weight on ACADIA Pharmaceuticals, Raises Price Target to $28
Benzinga · 08/25 15:28
Citigroup Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $40
Benzinga · 08/25 15:28
ACADIA Pharmaceuticals (ACAD) Gets a Buy from Deutsche Bank
TipRanks · 08/25 12:36
Acadia Pharmaceuticals price target raised to $38 from $37 at Deutsche Bank
TipRanks · 08/25 12:15
More
Webull provides a variety of real-time ACAD stock news. You can receive the latest news about Acadia Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About ACAD
Acadia Pharmaceuticals Inc.is a biopharmaceutical company. The Company is focused on innovation that makes the difference for underserved neurological and rare disease communities around the world. Its commercial portfolio includes the first and only FDA-approved treatments for Parkinson's disease psychosis and Rett syndrome. It is also developing therapeutic advancements with diverse pipelines that include mid- to late-stage programs in Alzheimer's disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. Its pipeline of product candidates includes Remlifanserin (formerly ACP-204), ACP-211, ACP-711, ACP-271, ACP-259, and Antisense Oligonucleotide (ASO) Program. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. DAYBUE (trofinetide) is developed for the treatment of Rett Syndrome.